Concourse Financial Group Securities, Inc. Immatics N.V. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share
Q3 2024 Oct 10, 2024	BUY	$10.93 - $12.92 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$9.78 - $13.49 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$10.23 - $12.94 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$7.36 - $10.89 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$11.01 - $12.62 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$11.01 - $12.62 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$5.92 - $12.72 $0 - $0
Q1 2023 May 15, 2023	BUY	$6.74 - $9.44 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$8.05 - $11.58 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$3.31 - $13.06 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$6.0 - $9.37 $0 - $0
Q1 2022 May 09, 2022	BUY	$6.64 - $12.85 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$10.81 - $14.38 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$11.58 - $15.46 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$10.43 - $12.81 $0 - $0
Q1 2021 May 13, 2021	BUY	$10.24 - $14.6 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$9.67 - $12.05 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$8.73 - $15.15 $0 - $0

Others Institutions Holding IMTX

# of Institutions

101

Shares Held

75.8M

Call Options Held

238K

Put Options Held

727K

Rtw Investments, LP New York, NY

10M
Shares

$71.1 Million
1.82% of portfolio
Wellington Management Group LLP Boston, MA

9.68M
Shares

$68.8 Million
0.02% of portfolio
Perceptive Advisors LLC New York, NY

8.09M
Shares

$57.5 Million
2.41% of portfolio
T. Rowe Price Investment Management, Inc. Baltimore, MD

7.38M
Shares

$52.5 Million
0.05% of portfolio
Baker Bros. Advisors LP New York, NY

6.44M
Shares

$45.8 Million
0.79% of portfolio

View Full List

About Immatics N.V.

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $542M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

More about IMTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account